α-Ketoglutarate links p53 to cell fate during tumour suppression.

Animals Carcinoma, Pancreatic Ductal / genetics Cell Differentiation / genetics Cell Line, Tumor Chromatin Assembly and Disassembly / drug effects Disease Models, Animal Gene Expression Regulation, Neoplastic / drug effects Ketoglutaric Acids / metabolism Mice Pancreatic Neoplasms / genetics Protein Binding Succinic Acid / metabolism Transcriptional Activation Tumor Suppressor Protein p53 / metabolism

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
09 2019
Historique:
received: 11 05 2018
accepted: 13 08 2019
pubmed: 20 9 2019
medline: 24 3 2020
entrez: 20 9 2019
Statut: ppublish

Résumé

The tumour suppressor TP53 is mutated in the majority of human cancers, and in over 70% of pancreatic ductal adenocarcinoma (PDAC)

Identifiants

DOI: 10.1038/s41586-019-1577-5 PMID: 31534224 PMC: PMC6830448
pubmed: 31534224
doi: 10.1038/s41586-019-1577-5
pii: 10.1038/s41586-019-1577-5
pmc: PMC6830448
mid: NIHMS1054359
doi:

Substances chimiques

Ketoglutaric Acids 0
Trp53 protein, mouse 0
Tumor Suppressor Protein p53 0
Succinic Acid AB6MNQ6J6L

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

595-599

Subventions

Organisme : NCI NIH HHS
ID : T32 CA160001
Pays : United States
Organisme : NCI NIH HHS
ID : R00 CA191021
Pays : United States
Organisme : Howard Hughes Medical Institute
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA087497
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA013106
Pays : United States
Organisme : NICHD NIH HHS
ID : T32 HD060600
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA204228
Pays : United States

Commentaires et corrections

Type : CommentIn

Références

Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495–501 (2015).
pubmed: 25719666 pmcid: 4523082 doi: 10.1038/nature14169
Kastenhuber, E. R. & Lowe, S. W. Putting p53 in context. Cell 170, 1062–1078 (2017).
pubmed: 28886379 pmcid: 5743327 doi: 10.1016/j.cell.2017.08.028
Kruiswijk, F., Labuschagne, C. F. & Vousden, K. H. p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell Biol. 16, 393–405 (2015).
pubmed: 26122615 doi: 10.1038/nrm4007
Morris, J. P. IV, Wang, S. C. & Hebrok, M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat. Rev. Cancer 10, 683–695 (2010).
pubmed: 20814421 pmcid: 4085546 doi: 10.1038/nrc2899
Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47–52 (2016).
pubmed: 26909576 doi: 10.1038/nature16965
Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
pubmed: 22541435 pmcid: 3472002 doi: 10.1016/j.cell.2012.01.058
Son, J. et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013).
pubmed: 23535601 pmcid: 3656466 doi: 10.1038/nature12040
Hingorani, S. R. et al. Trp53
pubmed: 15894267 doi: 10.1016/j.ccr.2005.04.023
Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349–361 (2012).
pubmed: 22265420 pmcid: 3266542 doi: 10.1016/j.cell.2011.11.025
Saborowski, M. et al. A modular and flexible ESC-based mouse model of pancreatic cancer. Genes Dev. 28, 85–97 (2014).
pubmed: 24395249 pmcid: 3894416 doi: 10.1101/gad.232082.113
Feldser, D. M. et al. Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468, 572–575 (2010).
pubmed: 21107428 pmcid: 3003305 doi: 10.1038/nature09535
Junttila, M. R. et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468, 567–571 (2010).
pubmed: 21107427 pmcid: 3011233 doi: 10.1038/nature09526
Martins, C. P., Brown-Swigart, L. & Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 127, 1323–1334 (2006).
pubmed: 17182091 doi: 10.1016/j.cell.2006.12.007
Xue, W. et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445, 656–660 (2007).
pubmed: 17251933 pmcid: 4601097 doi: 10.1038/nature05529
Carey, B. W., Finley, L. W., Cross, J. R., Allis, C. D. & Thompson, C. B. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature 518, 413–416 (2015).
pubmed: 25487152 doi: 10.1038/nature13981
Raffel, S. et al. BCAT1 restricts αKG levels in AML stem cells leading to IDH
pubmed: 29144447 doi: 10.1038/nature24294
Liu, P. S. et al. α-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat. Immunol. 18, 985–994 (2017).
pubmed: 28714978 doi: 10.1038/ni.3796
Brady, C. A. et al. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell 145, 571–583 (2011).
pubmed: 21565614 pmcid: 3259909 doi: 10.1016/j.cell.2011.03.035
Cheng, T. et al. Pyruvate carboxylase is required for glutamine-independent growth of tumor cells. Proc. Natl Acad. Sci. USA 108, 8674–8679 (2011).
pubmed: 21555572 pmcid: 3102381 doi: 10.1073/pnas.1016627108
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position. Nat. Methods 10, 1213–1218 (2013).
pubmed: 24097267 pmcid: 3959825 doi: 10.1038/nmeth.2688
Davie, K. et al. Discovery of transcription factors and regulatory regions driving in vivo tumor development by ATAC-seq and FAIRE-seq open chromatin profiling. PLoS Genet. 11, e1004994 (2015).
pubmed: 25679813 pmcid: 4334524 doi: 10.1371/journal.pgen.1004994
Hosoda, W. et al. Genetic analyses of isolated high-grade pancreatic intraepithelial neoplasia (HG-PanIN) reveal paucity of alterations in TP53 and SMAD4. J. Pathol. 242, 16–23 (2017).
pubmed: 28188630 pmcid: 5553451 doi: 10.1002/path.4884
Wellen, K. E. et al. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–1080 (2009).
pubmed: 19461003 pmcid: 2746744 doi: 10.1126/science.1164097
Cimmino, L. & Aifantis, I. Alternative roles for oxidized mCs and TETs. Curr. Opin. Genet. Dev. 42, 1–7 (2017).
pubmed: 27939598 doi: 10.1016/j.gde.2016.11.003
Yang, H. et al. Tumor development is associated with decrease of TET gene expression and 5-methylcytosine hydroxylation. Oncogene 32, 663–669 (2013).
pubmed: 22391558 doi: 10.1038/onc.2012.67
Xiao, M. et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326–1338 (2012).
pubmed: 22677546 pmcid: 3387660 doi: 10.1101/gad.191056.112
Kaelin, W. G., Jr & McKnight, S. L. Influence of metabolism on epigenetics and disease. Cell 153, 56–69 (2013).
pubmed: 23540690 pmcid: 3775362 doi: 10.1016/j.cell.2013.03.004
Schvartzman, J. M., Thompson, C. B. & Finley, L. W. S. Metabolic regulation of chromatin modifications and gene expression. J. Cell Biol. 217, 2247–2259 (2018).
pubmed: 29760106 pmcid: 6028552 doi: 10.1083/jcb.201803061
Ongusaha, P. P. et al. BRAC1 shifts p53-mediated cellular outcomes towards irreversible growth arrest. Oncogene 22, 3749–3758 (2003).
pubmed: 12802282 doi: 10.1038/sj.onc.1206439
Perez, C. A., Ott, J., Mays, J. & Pietenpol. J. A. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm. Oncogene 26, 7363–7370 (2007).
pubmed: 17563751 doi: 10.1038/sj.onc.1210561
Fridman, A. L. & Tainsky, M. A. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 27, 5975–5987 (2008).
pubmed: 18711403 doi: 10.1038/onc.2008.213
Kannan, K. et al. DNA microarrays identification of primary and secondary target genes regulated by p53. Oncogene 20, 2225–2234 (2001).
pubmed: 11402317 doi: 10.1038/sj.onc.1204319
Martínez-Cruz, A. B. et al. Spontaneous squamous cell carcinoma induced by the somatic inactivation of Retinoblastoma and Trp53 tumor suppressors. Cancer Res. 68, 683–692 (2008).
pubmed: 18245467 doi: 10.1158/0008-5472.CAN-07-3049
Tang, X., Milyavsky, M., Goldfinger, N. & Rotter, V. Amyloid-β precursor-like protein APLP1 is a novel p53 transcriptional target gene that augments neuroblastoma cell death upon genotoxic stress. Oncogene 26, 7302–7312 (2007).
pubmed: 17533371 doi: 10.1038/sj.onc.1210542
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
pubmed: 25557080 doi: 10.1016/j.cell.2014.12.021
Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437–450 (2003).
pubmed: 14706336 doi: 10.1016/S1535-6108(03)00309-X
Kawaguchi, Y. et al. The role of the transcriptional regulator Ptf1a in converting intestinal to pancreatic progenitors. Nat. Genet. 32, 128–134 (2002).
pubmed: 12185368 doi: 10.1038/ng959
Pan, F. C. et al. Spatiotemporal patterns of multipotentiality in Ptf1a-expressing cells during pancreas organogenesis and injury-induced facultative restoration. Development 140, 751–764 (2013).
pubmed: 23325761 pmcid: 3557774 doi: 10.1242/dev.090159
Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243–3248 (2001).
pubmed: 11751630 pmcid: 312845 doi: 10.1101/gad.943001
Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li–Fraumeni syndrome. Cell 119, 847–860 (2004).
pubmed: 15607980 doi: 10.1016/j.cell.2004.11.004
Marino, S., Vooijs, M., van Der Gulden, H., Jonkers, J. & Berns, A. Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev. 14, 994–1004 (2000).
pubmed: 10783170 pmcid: 316543 doi: 10.1101/gad.14.8.994
Beard, C., Hochedlinger, K., Plath, K., Wutz, A. & Jaenisch, R. Efficient method to generate single-copy transgenic mice by site-specific integration in embryonic stem cells. Genesis 44, 23–28 (2006).
pubmed: 16400644 doi: 10.1002/gene.20180
Dow, L. E. et al. Conditional reverse tet-transactivator mouse strains for the efficient induction of TRE-regulated transgenes in mice. PLoS ONE 9, e95236 (2014).
pubmed: 24743474 pmcid: 3990578 doi: 10.1371/journal.pone.0095236
Weissmueller, S. et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell 157, 382–394 (2014).
pubmed: 24725405 pmcid: 4001090 doi: 10.1016/j.cell.2014.01.066
Dickins, R. A. et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat. Genet. 37, 1289–1295 (2005).
pubmed: 16200064 doi: 10.1038/ng1651
Fellmann, C. et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Reports 5, 1704–1713 (2013).
pubmed: 24332856 doi: 10.1016/j.celrep.2013.11.020
Chen, C. et al. Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition. Genes Dev. 27, 1974–1985 (2013).
pubmed: 24065765 pmcid: 3792474 doi: 10.1101/gad.226613.113
Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783–784 (2014).
pubmed: 25075903 pmcid: 4486245 doi: 10.1038/nmeth.3047
Ruscetti, M. et al. NK cell-mediated cytotoxicity contributes to tumor control by a cytostatic drug combination. Science 362, 1416–1422 (2018).
pubmed: 30573629 pmcid: 6711172 doi: 10.1126/science.aas9090
Aksoy, O. et al. The atypical E2F family member E2F7 couples the p53 and RB pathways during cellular senescence. Genes Dev. 26, 1546–1557 (2012).
pubmed: 22802529 pmcid: 3404383 doi: 10.1101/gad.196238.112
Morris, J. P., IV et al. Dicer regulates differentiation and viability during mouse pancreatic cancer initiation. PLoS ONE 9, e95486 (2014).
pubmed: 24788257 pmcid: 4006805 doi: 10.1371/journal.pone.0095486
Zafra, M. P. et al. Optimized base editors enable efficient editing in cells, organoids and mice. Nat. Biotechnol. 36, 888–893 (2018).
pubmed: 29969439 pmcid: 6130889 doi: 10.1038/nbt.4194
Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
pubmed: 24695404 pmcid: 4103590 doi: 10.1093/bioinformatics/btu170
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
pubmed: 23104886
Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923–930 (2014).
pubmed: 24227677 doi: 10.1093/bioinformatics/btt656
Anders, S., Pyl, P. T. & Huber, W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166–169 (2015).
pubmed: 25260700
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
pubmed: 25516281 pmcid: 4302049
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
pubmed: 16199517 pmcid: 1239896 doi: 10.1073/pnas.0506580102
Millard, P., Letisse, F., Sokol, S. & Portais, J. C. IsoCor: correcting MS data in isotope labeling experiments. Bioinformatics 28, 1294–1296 (2012).
pubmed: 22419781 doi: 10.1093/bioinformatics/bts127
Buenrostro, J. D., Wu, B., Chang, H. Y. & Greenleaf, W. J. ATAC-seq: a method for assaying chromatin accessibility genome-wide. Curr. Protoc. Mol. Biol. 109, 21.29.1–21.29.9 (2015).
doi: 10.1002/0471142727.mb2129s109
Kenzelmann Broz, D. et al. Global genomic profiling reveals an extensive p53-regulated autophagy program contributing to key p53 responses. Genes Dev. 27, 1016–1031 (2013).
pubmed: 23651856 pmcid: 3656320 doi: 10.1101/gad.212282.112

Auteurs

John P Morris (JP)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Jossie J Yashinskie (JJ)

Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Weill Cornell Graduate School of Medical Sciences, Cornell University, New York, NY, USA.

Richard Koche (R)

Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Rohit Chandwani (R)

Department of Surgery, Weill Cornell Medical College, New York, NY, USA.
Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Cell and Developmental Biology, Weill Cornell Medical College, New York, NY, USA.

Sha Tian (S)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Chi-Chao Chen (CC)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Timour Baslan (T)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Zoran S Marinkovic (ZS)

Department of Biology, Center for Genomics and Systems Biology, New York University, New York, NY, USA.

Francisco J Sánchez-Rivera (FJ)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Steven D Leach (SD)

Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.

Carlos Carmona-Fontaine (C)

Department of Biology, Center for Genomics and Systems Biology, New York University, New York, NY, USA.

Craig B Thompson (CB)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Lydia W S Finley (LWS)

Cell Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. finleyl@mskcc.org.
Center for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA. finleyl@mskcc.org.

Scott W Lowe (SW)

Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lowes@mskcc.org.
Howard Hughes Medical Insitute, Janelia Research Campus, Ashburn, VA, USA. lowes@mskcc.org.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › Carcinome du canal pancréatique › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Différenciation cellulaire › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Assemblage et désassemblage de la chromatine › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Cétoacides › Acides cétoglutariques › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs du pancréas › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Métabolisme › Liaison aux protéines › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Composés chimiques organiques › Acides carboxyliques › Acides acycliques › Diacides carboxyliques › Succinates › Acide succinique › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Activation de la transcription › α-Ketoglutarate links p53 to cell fate during...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › α-Ketoglutarate links p53 to cell fate during...